Novo Nordisk leads the sector in spending on shareholder enrichment: With a ratio of 1.41, Novo Nordisk spent 41% more on shareholder returns (buybacks and dividends) compared to R&D, making it the highest spender on shareholder enrichment among 15 peer companies 9 in the pharmaceutical sector
Dosing protocols often mirror FDA-approved medication guidelines, but quality and consistency may vary between compounding pharmacies
C., Sarwer, D
Okubo, R., Ohigashi, T., Kondo, M., Tsunoda, R., Kai, H., Saito, C., et al
Formulation and handling follow defined procedures designed to support stable, repeatable research compound preparation